AIM
UTHR icon

Access Investment Management’s United Therapeutics UTHR Stock Holding History

Access Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,171
Closed -$1.29M – 161
2026
Q1 		$1.29M Sell
2,171
-5,349
-71% -$2.66M 0.34% 48
2025
Q4 		$3.15M Hold
7,520
– – 0.85% 35
2025
Q3 		$3.15M Buy
7,520
+65
+0.9% +$21.9K 0.85% 35
2025
Q2 		$2.14M Buy
+7,455
New +$2.23M 0.61% 41
2024
Q4 		$2.59M Buy
7,335
+55
+0.8% +$20.2K 0.75% 38
2024
Q3 		$2.61M Buy
7,280
+15
+0.2% +$5.07K 0.79% 36
2024
Q2 		$2.31M Buy
7,265
+55
+0.8% +$14.6K 0.75% 38
2024
Q1 		$1.66M Buy
7,210
+4,170
+137% +$941K 0.55% 40
2023
Q4 		$668K Buy
+3,040
New +$701K 0.25% 53

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Access Investment Management's UTHR Position: Q2 2026 in Review

Access Investment Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 2,171 shares — an estimated $1.29M sold.

Access Investment Management first reported a position in UTHR in Q4 2023 and held it in 9 quarters. The position peaked at $3.15M in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Access Investment Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Access Investment Management sold 2,171 United Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Access Investment Management first reported a position in United Therapeutics in Q4 2023 and held it in 9 quarters.
  • Access Investment Management's United Therapeutics position peaked at $3.15M in Q4 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Access Investment Management's 13F filing for Q2 2026, filed 3 Aug 2026.